Omega Fund Management

Latest statistics and disclosures from Omega Fund Management's latest quarterly 13F-HR filing:

  • Top 5 stock holdings are REPL, MORF, GOSS, ARQT, IMUX, and represent 81.47% of Omega Fund Management's stock portfolio.
  • Added to shares of these 4 stocks: TRVI, REPL, MORF, PRTK.
  • Reduced shares in these 5 stocks: TBIO (-$24.30M), GOSS (-$12.42M), PRVL, EPIX, CDTX.
  • Sold out of its positions in TBIO.
  • Omega Fund Management was a net seller of stock by $37.75M.
  • Omega Fund Management has $365.74M in assets under management (AUM), growing by 51.37%.

Portfolio Holdings for Omega Fund Management

Companies in the Omega Fund Management portfolio as of the June 2020 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Replimune Group Common Stock (REPL) 36.13 $132.16M 5.34M 24.73
Morphic Holding Common Stock (MORF) 22.01 $80.49M 2.98M 27.05
Gossamer Bio Common Stock (GOSS) 11.80 $43.17M -22% 3.32M 13.00
Arcutis Biothereapeutics Common Stock (ARQT) 6.98 $25.54M 844.68k 30.24
Immunic Common Stock (IMUX) 4.55 $16.62M 1.37M 12.12
Paratek Pharmaceuticals Common Stock (PRTK) 3.71 $13.59M 2.60M 5.22
ESSA Pharma Common Stock (EPIX) 2.54 $9.28M -11% 1.50M 6.20
Trevi Therapeutics Common Stock (TRVI) 2.48 $9.05M +8% 1.38M 6.58
Beam Therapeutics Common Stock (BEAM) 2.32 $8.48M 302.82k 28.00
Cidara Therapeutics Common Stock (CDTX) 2.02 $7.40M 2.01M 3.69
ObsEva Common Stock (OBSV) 1.61 $5.89M 999.36k 5.89
FibroGen Common Stock (FGEN) 1.45 $5.30M 130.65k 40.53
Jounce Therapeutics Common Stock (JNCE) 1.00 $3.66M 529.97k 6.90
Prevail Therapeutics Common Stock (PRVL) 0.76 $2.79M -31% 187.54k 14.90
Pieris Pharmaceuticals Common Stock (PIRS) 0.64 $2.33M 750.74k 3.10

Past Filings by Omega Fund Management

SEC 13F filings are viewable for Omega Fund Management going back to 2014

View all past filings